8 October 2024 UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101.
One of the pioneers of mRNA technologies, BioNTec, is investing the proceeds of its work during the pandemic on its original focus - cancer vaccines. 6 January 2023
The US Food and Drug Administration (FDA) yesterday accepted Biologics License Applications (BLAs) from Swiss pharma giant Roche and Belgium’s UCB, and granted them accelerated review. 6 January 2023
Adding to a deal with a US pharma giant last year, Cambridge, USA-based biotech Orna Therapeutics has now entered into a collaboration with Shanghai Xianbo Biotech, also known as Simnova outside of China, to discover, develop and commercialize multiple potential therapeutics in the area of oncology in China. 6 January 2023
One of the world’s leading specialists in mRNA therapeutics has partnered with California’s CytomX Therapeutics to create novel cancer meds. 6 January 2023
Professional services company PwC has released a new report, PwC’s Next In Pharma and Life Sciences 2023 Report. This highlights the outlook for the pharmaceutical and life sciences industry, and the biggest c-suite agenda topics that will shape 2023. 6 January 2023
Mergers and acquisition (M&A) activity in India is heating up. The surge in transactions in the pharmaceutical industry saw 16 deals during 2022 - seemingly the largest number in a decade, worth several billion dollars in value. 6 January 2023
US immunology specialist Acelyrin has acquired ValenzaBio, a privately-held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. 5 January 2023
US precision medicines firm Frontier Medicines today announced the second and third programs under the company's global partnership with AbbVie have advanced into lead generation. 5 January 2023
Privately held Danish biotechnology company MinervaX has appointed Lidia Oostvogels as chief medical officer, bringing a wealth of experience in vaccine development with more than 25 years’ experience in clinical development. 5 January 2023
US biotech star-up Capsida Biotherapeutics has entered a multi-year strategic collaboration with pharma major Eli Lilly’s subsidiary Prevail to develop transformative genetic medicines for serious diseases. 5 January 2023
It has been a long road for Geron’s telomerase blocker, but the company is now finally planning a commercial launch for imetelstat in 2024. 5 January 2023
A report from industry commentator GlobalData highlights the potential for cell therapies to transform the treatment of multiple sclerosis (MS). 5 January 2023
UK pharma major AstraZeneca said today that its Biologics License Application (BLA) for nirsevimab has been accepted for review by the US Food and Drug Administration (FDA) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. 5 January 2023
Finnish drugmaker Orion Corporation says it has signed a long-term license agreement with US drugmaker Amneal Pharmaceuticals, to commercialize Amneal’s generic products in Orion territories. 5 January 2023
US cancer specialist Spectrum Pharmaceuticals has lost more than 50% of its stock market value in the past six months, and it has now lost a member of its beleaguered management team, too. 4 January 2023
Taking advantage of the vast cash pile generated by the success of its COVID-19 vaccine Spikevax, US mRNA therapeutics and vaccines specialist Moderna (Nasdaq: MRNA) today announced its first out-right acquisition since its launch in 2020. 4 January 2023
UK-based ADVANZ PHARMA has acquired exclusive rights to register and commercialize AT-007, a Phase III development compound for the treatment of several rare neurological diseases, including galactosemia and SORD deficiency, in the European Economic Area, the UK, and Switzerland. 4 January 2023
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
Sage Therapeutics’ share price fell 11% to $6 in pre-market activity on Tuesday, after it announced disappointing top-line results from LIGHTWAVE. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
The UK has launched a new Regulatory Innovation Office (RIO), with the goal of accelerating new technologies, particularly in sectors like biotech and healthcare, by reducing regulatory barriers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Some two-and-a-half years after buying the Novo Holdings portfolio company ReViral and its respiratory syncytial virus (RSV) candidate sisunatovir in a deal worth up to $525 million, US pharma giant Pfizer may have signalled an early end to the pricey project. 9 October 2024
US pharma major Bristol Myers Squibb’s recent approval from the US Food and Drug Administration (FDA) for Cobenfy (xanomeline and trospium chloride) for the treatment of adults with schizophrenia is a win for the company. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.